Arhalofenate

DB11811InvestigationalSmall molecule

Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia.

Mechanism: Partial agonist of peroxisome proliferator-activated receptor (PPAR) gamma; results in improved glucose, lipid, and weight management.
Curator reviewed
Formula / weight: C₁₉H₁₇ClF₃NO₄ · 415.79 g/mol (avg)
Code names: CB-102 · JNJ-39659100 · M-102 · MBX-102

Resolves to

Compound

Structure

InChIKeyBJBCSGQLZQGGIQ-QGZVFWFLSA-NSMILESCC(=O)NCCOC(=O)[C@H](OC1=CC=CC(=C1)C(F)(F)F)C1=CC=C(Cl)C=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Arhalofenate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.